@Article{Barylski2018,
journal="Lekarz POZ",
issn="2450-3517",
volume="4",
number="1",
year="2018",
title="Fenofibrate in light of the latest guidelines for the management of dyslipidaemia – why is non-HDL cholesterol so important?",
abstract="Combined lipid disorders, including increased plasma triglycerides levels, low HDL-C, and small, dense LDL particles, comprise atherogenic dyslipidaemia. Observational and clinical studies have shown that these lipid abnormalities are strongly associated with increased risk of macro- and microvascular events even in patients with LDL-C level at goal after statin therapy. Combination pharmacotherapy may significantly improve lipid profile and have a significant impact on cardiovascular risk reduction, which is reflected in the non-HDL cholesterol concentration, the secondary target of treatment in the latest guidelines.",
author="Barylski, Marcin",
pages="27--32",
url="https://www.termedia.pl/Fenofibrate-in-light-of-the-latest-guidelines-for-the-management-of-dyslipidaemia-why-is-non-HDL-cholesterol-so-important-,98,32206,1,1.html"
}